Category - Developments

Developments

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...

December 30, 2021

Developments

Titan Pharmaceuticals to explore strategic alternatives

Titan Pharmaceuticals (NASDAQ:TTNP) engaged Maxim Group as its exclusive financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be...

December 21, 2021

Developments

FDA clears Hepion IND for CRV431 in treatment of liver cancer

The FDA accepted Hepion Pharmaceuticals’ (NASDAQ:HEPA) IND application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Liver cancer is the sixth most...

December 21, 2021

Developments

Altamira randomizes first patients in Bentrio trial in house dust mite allergy

Altamira Therapeutics (NASDAQ:CYTO) randomized the first group of patients in a clinical trial with Bentrio (AM-301) in house dust mite allergic rhinitis. Bentrio, a drug-free nasal spray intended for personal...

December 16, 2021

Developments

Cidara, Mundipharma post positive Phase 3 results for rezafungin in candidemia, invasive candidiasis

Cidara Therapeutics (NASDAQ:CDTX) and Mundipharma reported positive topline data from the ReSTORE Phase 3 clinical trial, evaluating the efficacy and safety of its once-weekly antifungal...

December 15, 2021

Developments

Precigen reports positive interim Phase 1 data in r/r AML

Precigen (NASDAQ:PGEN) presented positive interim data at the ASH annual meeting from an ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T in patients with relapsed or refractory (r/r) acute myeloid leukemia...

December 14, 2021

Developments

OpSens files 510(k) submission for new guidewire for TAVR procedure

OpSens (TSX:OPS; OTCQX:OPSSF) filed a 510(k) submission with the FDA for regulatory clearance of its new SavvyWire guidewire for transcatheter aortic valve replacement, or TAVR procedures. OpSens previously filed for...

December 13, 2021

Developments

ENDRA, King ’s College Hospital in TAEUS clinical study for NAFLD

ENDRA Life Sciences (NASDAQ:NDRA) is partnering with King’s College Hospital, London (KCH) for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound (TAEUS) device for assessing non-alcoholic fatty liver...

December 13, 2021

Developments

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

The United States Patent and Trademark Office (USPTO) has granted a new U.S. patent for Palisade Bio’s (NASDAQ:PALI) lead investigational drug product, LB1148, for use in treating adhesions and postoperative ileus...

December 8, 2021

Developments

Cognetivity, Ketamine One collaborating on depression, PTSD studies

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) entered a collaborative partnership with Ketamine One Capital to study and develop assessments for depression and post-traumatic stress disorder (PTSD). In the...

December 7, 2021

Category - Developments

Subscribe